


Analysis of Per - and Polyfluoroalkyl Substances (PFAS)




Conditions

- System** : Agilent1260 Infinity II Prime LC System
 Agilent Ultivo Triple Quadrupole LC/MS system
- Column** : InertSustain AQ-C18 (1.9 μm 100 x 2.1 mm I.D.) (GL Sciences Inc.)
- Column Cat. No.** : 5020-89939
- Delay Column** : Delay Column for PFAS (30 x 3.0 mm I.D.) (GL Sciences Inc.)
- Delay Column Cat. No.** : 5020-90005
- Eluent** : A) CH_3CN
 B) 2 mmol/L $\text{CH}_3\text{COONH}_4$ in H_2O

Time (min)	A%	B%
0	10	90
1.5	30	70
10.0	100	0
11.0	100	0
11.1	10	90
15.0	10	90

- Flow Rate** : 0.3 mL/min
- Col. Temp.** : 40 $^\circ\text{C}$
- Detection** : LC/MS/MS (ESI, Negative, SRM)
- Drying Gas Temp.** : 300 $^\circ\text{C}$
- Drying Gas Folw Rrte** : 10 L/min
- Sheath Gas Temp.** : 400 $^\circ\text{C}$
- Sheath Gas Folw Rrte** : 12 L/min
- Nebulizer gas pressure** : 50 psi
- Injection Vol.** : 2 μL
- Sample** : Standard in Methanol (each 5 ng/mL)

No.	Compounds	RT(min)	Transition 1			Transition 2		
			Q1	Q3	CE	Q1	Q3	CE
1	PFPrA	2.46	163	119	-10			
2	PFBA	4.61	213	169	-6			
3	PFPeA	5.41	263	219	-6			
4	PFPrS	5.50	249	99	-30	249	80	-45
5	PFHxA	6.04	313	269	-6	313	119	-22
6	PFBS	6.27	299	80	40	299	99	-34
7	HFPO-DA(GenX)	6.29	285	169	-4	285	185	-16
8	PFHpA	6.61	363	319	-6	363	169	-18
9	ADONA(DONA)	6.81	377	251	-8	377	85	-40
10	6:2 FTSA	6.85	427	407	-23	427	81	-44
11	PFOA	7.12	413	369	-10	413	169	-15
12	8:2 FTUCA	7.29	457	393	-12	457	343	-44
13	PFHxS	7.40	399	80	-53	399	99	-45
14	PFNA	7.61	463	419	-10	463	219	-18
15	8:2 FTSA	7.80	527	507	-28	527	81	-55
16	PFHpS	7.94	449	80	-55	449	99	-51
17	N-MeFOSAA	8.00	570	419	-20	570	483	-16
18	PFDA	8.08	513	469	-6	513	269	-18
19	10:2 FTUCA	8.21	557	493	-16	557	243	-44
20	N-EtFOSAA	8.23	584	419	-20	584	483	-16
21	PFOS	8.41	499	80	-60	499	99	-55
22	PFUnDA(PFUnA)	8.51	563	519	-7	563	269	-16
23	9Cl-PF3ONS	8.78	531	351	-28	531	83	-32
24	PFDoDA(PFDoA)	8.95	613	569	-9	613	319	-22
25	PFDS	9.26	599	80	-65	599	99	-60
26	PFTrDA(PFTrA)	9.36	663	619	-9	663	169	-29
27	FOSA(PFOSA)	9.61	498	78	-75	498	169	-30
28	PFTeDA(PFTeA)	9.76	713	669	-10	713	169	-33
29	8:2 diPAP	10.43	989	97	-45	989	543	-28
30	PFHxDA	10.46	813	769	-12	813	219	-32
31	PFOcDA(PFODA)	11.02	913	869	-11	913	169	-39
32	N-MeFOSA	11.04	512	169	-27	512	219	-23
33	N-EtFOSA	11.37	526	219	-23	526	169	-27



No.	Compounds	RT(min)	Transition		
			Q1	Q3	CE
1	$^{13}\text{C}_4$ -PFBA	4.61	217	172	-6
2	$^{13}\text{C}_5$ -PFPeA	5.41	268	223	-4
3	$^{13}\text{C}_5$ -PFHxA	6.04	318	273	-4
4	$^{13}\text{C}_3$ -PFBS	6.27	302	80	-40
5	$^{13}\text{C}_3$ -HFPO-DA($^{13}\text{C}_3$ -GenX)	6.29	287	169	-4
6	$^{13}\text{C}_4$ -PFHpA	6.60	367	322	-8
7	$^{13}\text{C}_2$ -6:2 FTSA	6.86	429	409	-24
8	$^{13}\text{C}_8$ -PFOA	7.12	421	376	-8
9	$^{13}\text{C}_2$ -8:2 FTUCA	7.29	459	394	-16
10	$^{13}\text{C}_3$ -PFHxS	7.43	402	80	-65
11	$^{13}\text{C}_9$ -PFNA	7.61	472	427	-8
12	$^{13}\text{C}_2$ -8:2 FTSA	7.79	529	509	-27
13	d_3 -N-MeFOSAA	7.99	573	419	-20
14	$^{13}\text{C}_6$ -PFDA	8.07	519	474	-8
15	d_5 -N-EtFOSAA	8.21	589	419	-20
16	$^{13}\text{C}_8$ -PFOS	8.41	507	80	-58
17	$^{13}\text{C}_7$ -PFUnDA($^{13}\text{C}_7$ -PFUnA)	8.51	570	525	-8
18	$^{13}\text{C}_2$ -PFDoDA($^{13}\text{C}_2$ -PFDoA)	8.94	615	570	-8
19	$^{13}\text{C}_8$ -FOSA($^{13}\text{C}_8$ -PFOSA)	9.74	506	78	-49
20	$^{13}\text{C}_2$ -PFTeDA($^{13}\text{C}_2$ -PFTeA)	9.76	715	670	-7
21	$^{13}\text{C}_4$ -8:2 diPAP	10.42	993	545	-19
22	$^{13}\text{C}_2$ -PFHxDA	10.46	815	770	-12
23	d_3 -N-MeFOSA	11.03	515	169	-30
24	d_5 -N-EtFOSA	11.36	531	169	-30